Learn More
BACKGROUND Enoxaparin dosage for obese patients and patients with renal impairment remains controversial. OBJECTIVE To compare anti-factor Xa activity (anti-Xa) among obese and renal impairment patients to patients with healthy weight and adequate renal function. DESIGN Open, prospective, nonrandomized clinical trial. SETTING A major community(More)
OBJECTIVE Statins have been shown to reduce the risk of major cardiovascular disease. We recognize that there is a major gap between the use of statins in actual practice and treatment guidelines for dyslipidemia. Low adherence to statins may have a significant impact on clinical issues and health-care costs. The objective is to evaluate the impact of low(More)
In hospitalized patients, venous thromboembolism (VTE) is an important cause of morbidity and mortality. Despite evidence demonstrating efficacy and safety of pharmacological thromboprophylaxis in the prevention of VTE, its use remains low. The aim of this study is to compare the incidence of use of thromboprophylaxis before and after a pharmacy-led(More)
The authors compared the abilities of descriptive and valuational health-related quality-of-life measures to discriminate healthy participants (n=39) from those on diets for dyslipidemia (n=35) and angina patients (n=30). On the rating scale, the time tradeoff, and the General Health Perception subscale of the SF-36 Health Survey, the participants with(More)
AIMS Statins have been shown to significantly reduce morbidity and mortality in patients with coronary artery disease (CAD), and also in patients with dyslipidaemia when statins are taken regularly. Middle-aged patients have the highest level of forecasting benefit and little is known about persistence rate of these therapies in a real-life setting. The(More)
AIM Statins have been shown to significantly reduce morbidity and mortality both in patients with coronary artery disease and in those with dyslipidemia when they are taken regularly. Middle-aged patients have the highest level of forecasting benefit, and little is known about the persistence rate of these therapies in a real-life setting.Objective. To(More)
BACKGROUND Statins reduce cardiovascular morbidity and mortality after continuous treatment. Studies have shown that less than 50% of patients take 80% or more of prescribed doses 1 year after starting therapy. OBJECTIVE To evaluate the impact of statin adherence on the incidence of coronary artery disease (CAD). METHODS A cohort of 115,290 patients was(More)
BACKGROUND Cardiovascular diseases (CVD) represent a heavy economic burden on individuals, health services, and society. Low adherence to antihypertensive (AH) agents is acknowledged as a major contributor to the lack of blood pressure control, and may have a significant impact on clinical outcomes and healthcare costs. OBJECTIVES To evaluate the impact(More)
BACKGROUND Evidence from meta-analyses shows that statin therapy reduces all-cause mortality and nonhemorrhagic strokes. Nonadherence to statins may reduce this protective effect. The association between statin adherence and incidence of cerebrovascular disease remains unexplored outside the context of clinical trials. OBJECTIVE To evaluate the impact of(More)
AIMS Statins are effective in the prevention of an atherosclerotic event, e.g. coronary artery disease and cerebrovascular disease. Patients at high risk of cardiovascular disease (CVD), such as chronic heart failure (CHF), might benefit from the effects of statin therapy. However, one question that has not yet been answered and that may clarify the role of(More)